80046151 - What's New in Diabetic Retinopathy and Venous Occlusive Disease?

What's New in Diabetic Retinopathy and Venous Occlusive Disease? Banner


Date & Location
Wednesday, September 26, 2018, 7:30 AM - 5:00 PM, Tilghman Auditorium, Baltimore, MD

Target Audience
Ophthalmology, Optometry

Overview
The total number of people worldwide with diabetes mellitus is projected to rise from 171 million in 2000 to 366 million in 2030. In the United States, almost 24 million or 8 percent of the population has diabetes mellitus. Approximately 4.0 million Americans age 40 and older have diabetic retinopathy, 900,000 of whom have vision threatening disease, defined as pre-proliferative retinopathy, macular edema, or both. Diabetic retinopathy remains the leading cause of blindness in adults who make up the work force. Despite this, diabetic retinopathy and venous occlusive disease are often under-diagnosed and under-treated. This annual course highlights new information being reported by the Diabetic Retinopathy Clinical Research Network and others, which will impact current standard care and management strategies.

Fees
Physicians .................................................................................................................................................................... $ 325
Residents*/Fellows*/Nurses/NPs/PAs/Allied Health Professionals............................................. ........$ 225
*with verification of status

Late Fee and Refund Policy
A $50 late fee applies to registrations received after 5:00 p.m. ET on September 20, 2018. A handling fee of $50 will be deducted for cancellation. An additional fee may apply for cancellation of other events, including workshops and social activities. Refund requests must be received by fax or mail by September 20, 2018. No refunds will be made thereafter. Transfer of registration to another Johns Hopkins activity in lieu of cancellation is not possible.



Objectives
  1. Summarize the evidence of relation of diabetic control to incidence and severity of retinopathy.
  2. Diagnose diabetic macular edema, severe non-proliferative diabetic retinopathy, and high risk proliferative diabetic retinopathy.
  3. Determine how best to manage diabetic macular edema, severe non-proliferative diabetic retinopathy, and high risk proliferative diabetic retinopathy.
  4. Recognize new experimental treatment options.

Accreditation
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Credit
The Maryland Board of Examiners in Optometry has approved this activity for 7 hours of CE credit. Approval Code: 2019-001 PS